Head-to-head · WeighScore
AVARA Rx vs Effecty
By GLP-1 ScorecardUpdated
Score comparison
Effecty has the higher recorded score — 83.7/100 to 62.8/100.
Effecty grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Separate compounded/branded offers; confirm discounts, billing and exit terms.
Before you choose
Before comparing the headline prices, the AVARA Rx review and the Effecty review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, AVARA Rx vs Gala Health and Balanced Hormone Health vs Effecty compare each of them with another graded program, and the list of alternatives to AVARA Rx ranks the programs closest to AVARA Rx on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the GoodLife Health review covers one graded close to these two, at 69.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | AVARA Rx | Effecty |
|---|---|---|
| WeighScore | 62.8/100 | 83.7/100 |
| Grade | C | B |
| Site position | #285 | #21 |
| Semaglutide | Personalized "GLP-1" (drug not named) starting at $229 | $170/month before code; advertised $95 first month. Supply unconfirmed. |
| Tirzepatide | Personalized "GLP-1/GIP" (drug not named) starting at $279 | $235/month before code; advertised $160 first month. Supply unconfirmed. |
| Coverage | All 50 states | Nationwide shipping claimed; confirm treatment-specific eligibility. |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Names its pharmacy partner (DiRx Health, Ft Lauderdale FL) — buyers can independently verify its licensure
- Names its clinical network (Beluga Health) — you can research the platform handling your prescriptions
- All 50 states explicitly listed on the FAQ — uncommon vs peers that just say 'nationwide'
- Patient-friendly refunds — full refund if a provider disqualifies you, partial if a weaker dose is prescribed
- LegitScript verification badge displayed; pharmacy claims NABP-accredited facilities
What to consider
- Operating legal entity not disclosed — only a Sheridan, WY registered-agent-style address surfaced
- Dose pricing not itemized — only 'starting at $229' for GLP-1 and 'starting at $279' for GLP-1/GIP, without naming either drug
- LegitScript certification number not shown — badge only, so no direct lookup
- No named medical director (Beluga Health is the network, not a named MD)
- Lab work requirements not specified, and consultation fee not broken out from medication cost
Strengths
- Medication-specific billing terms
- Dose-independent pricing advertised
- Separate Wegovy offer published
What to consider
- Selected total/supply unconfirmed
- Prescription sales described as final
- Assigned pharmacy and individual credentials unverified
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.